cardiac arrhythmia suppression trial cast doubleblind randomized controlled study designed test hypothesis suppression premature ventricular complexes pvc class antiarrhythmic agents myocardial infarction mi would reduce mortality conducted included patients study found tested drugs increased mortality instead lowering publication results combination large followup studies drugs tested cast led paradigm shift treatment mi patients class iii antiarrhythmics used extreme caution mi contraindicated heart rhythm society distinguished scientist george wyse member cast trials steering executive committeescitation needed study prompted fact patients suffer myocardial infarctions mis high risk sudden death presumably due arrhythmia around time study onset estimated patients would die subsequent year following mi half deaths resulting arrhythmia warranted investigation whether pvc suppression could improve outcomes postmi patients trial conducted national heart lung blood institutecitation needed cast multicenter doubleblind randomized controlled trial patients randomized drug therapy placebo met criteria myocardial infarction occurring six days two years prior onset study asymptomatic ventricular premature beats detected holter monitor could suppressed either encainide flecainide moracizine openlabel design total subjects responded randomized encainide flecainide placebo moracizine placebo primary endpoint sudden cardiac death secondary endpoint allcause mortalitycitation needed second cardiac arrhythmia suppression trial cast ii modified enrollment criteria include patients higher risk serious included patients enrolled within days previous mi left ventricular ejection fraction lower prior enrollment suppression pvcs occurred drugs vs placebo using doubleblinded design patients serious arrhythmias would also includedcitation needed drugs used encainide flecainide moracizine successfully reduced amount pvcs led arrhythmiarelated deaths total mortality significantly higher encainide flecainide mean followup period months within two years enrollment encainide flecainide discontinued increased mortality sudden cardiac death cast ii compared moracizine placebo also stopped early within two weeks cardiac death moracizine group longterm survival seemed highly unlikely excess mortality attributed proarrhythmic effects agents class antiarrhythmics proarrhythmic heart ischemia animals httpsenwikipediaorgwikicardiacarrhythmiasuppressiontrial